Search Results

You are looking at 131 - 140 of 868 items for :

  • Refine by Access: All x
Clear All
Full access

Identification of a Novel Fusion Gene, IRF2BP2-RARA, in Acute Promyelocytic Leukemia

C. Cameron Yin, Nitin Jain, Meenakshi Mehrotra, Jianhua Zhagn, Alexei Protopopov, Zhuang Zuo, Naveen Pemmaraju, Courtney DiNardo, Cheryl Hirsch-Ginsberg, Sa A. Wang, L. Jeffrey Medeiros, Lynda Chin, Keyur P. Patel, Farhad Ravandi, Andrew Futreal, and Carlos E. Bueso-Ramos

experienced relapse 2 months after completion of consolidation therapy. She then received salvage therapy with ATRA, arsenic trioxide, and idarubicin, followed by haploidentical bone marrow transplantation. At the time of writing, she was experiencing complete

Full access

The Role of Maintenance Therapy in the Treatment of Multiple Myeloma

Ashraf Z. Badros

orally on days 1 to 4 of a 28-day cycle produced a similar median duration of remission, but significantly fewer patients treated with dexamethasone maintenance responded to repeat melphalan/dexamethasone at relapse relative to those treated with

Full access

Allogeneic Stem Cell Transplantation for Philadelphia Chromosome–Positive Acute Myeloid Leukemia

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage

.2) translocation, which results in the Ph chromosome, can occur in AML as a de novo chromosomal aberration with or without additional abnormalities or as a therapy-related event. 2 , 9 In de novo cases, it may be present at AML diagnosis or relapse. 1 , 10 , 11

Full access

Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma

Alexandra K. Zaleta, Melissa F. Miller, Julie S. Olson, Eva Y.N. Yuen, Thomas W. LeBlanc, Craig E. Cole, Shauna McManus, and Joanne S. Buzaglo

, or other/multiracial), Hispanic ethnicity, region, annual household income, education (dichotomized as whether the patient graduated from college), and employment status. Participants also reported years since MM diagnosis, history of relapse, history

Full access

Intermittent Versus Continuous Androgen Deprivation Therapy

Celestia S. Higano

therapy for prostate cancer, often called biochemical relapse . These men had no symptoms of cancer, yet were often treated with ADT because of concern for cancer progression. The side effects and toxicities of ADT became more apparent and assumed greater

Full access

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

Tumor Size: Tumor size is a well-established independent prognostic factor for breast cancer, with the risk of relapse increasing as tumor size increases, regardless of axillary lymph node status ( Table 1 ). 5 , 6 Recent Surveillance, Epidemiology, and

Full access

QIM19-134: Improving Access to Bone Marrow Transplant in the Community: The Memorial Sloan Kettering Cancer Alliance Shared Care Program

Craig Sauter, W. Jeffrey Baker, Elizabeth Rodriguez, Silvia Willumsen, Barbara Morcerf, Kristi Gafford, Jessica Kennington, Richard Korman, Peter Yu, David Pfister, and Sergio Giralt

like infectious disease and dermatology; and research, including an MSK clinical trial open at HHC to identify and understand barriers to transplant in the community for patients with newly diagnosed or relapsed acute leukemia. Results: Since November

Full access

HSR19-106: Association Between Pathological Complete Responses and Long-Term Survival Outcomes Among Triple-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Cynthia Z. Qi, Min Huang, Amin Haiderali, Jipan Xie, Zheng-Yi Zhou, Eric Q. Wu, and Peter Fasching

=19), disease-free survival (DFS; N=14), relapse-free survival (RFS; N=7), event-free survival (N=5), distant DFS (N = 4), and local RFS (N=2). Kaplan-Meier analysis was used to assess the association between pCR and these outcomes in 31 studies. Clear

Full access

HSR19-107: Nivolumab for Newly Diagnosed Classical Hodgkin Lymphoma: Patient-Reported Outcomes From CheckMate 205 Cohort D

Radhakrishnan Ramchandren, Stephen M. Ansell, Philippe Armand, Andreas Engert, Fiona Taylor, Kim Cocks, Clara Chen, Bryan Bennett, Alejandro Moreno-Koehler, Adam Roeder, Anne Sumbul, Mariana Sacchi, and David Cella

checkpoint inhibitor monoclonal antibody, demonstrated efficacy and clinically meaningful improvement in pt-reported outcomes (PROs) in pts with relapsed/refractory cHL in cohorts A, B, and C of CheckMate 205 (NCT02181738) (Armand et al, J Clin Oncol 2018

Full access

EPR19-070: Incidence Pattern of Malignant Lymphoma by Cell-Lineage/Cell-Maturity Status in Nagasaki, Japan, 1985–2012: Preliminary Results

Thi My Hanh Luong, Daisuke Niino, Hisayoshi Kondo, Shiro Miura, Masahiro Nakashima, and Masako Iwanaga

Nagasaki Prefectural Cancer Registry. From those, we excluded 1,477 records because of codes other than ML, diagnosed before 1985, and possible relapse records of identical cases. Records based on ICD-O-1 or ICD-O-2 were substituted by the corresponding ICD